Status:
COMPLETED
Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Hepatocellular carcinoma (HCC) can present itself in many forms (size, number of lesions) for the treatment of which a therapeutic panel can be elaborated and layered. If a curative treatment cannot b...
Eligibility Criteria
Inclusion
- a HCC treated by TACE followed by RFA, MWA and/or CK
- from 01/2010 to 12/2020
- treated by Nancy Regional University Hospital (TACE, RFA, MWA) and Institut de Cancérologie de Lorraine (CK)
Exclusion
- Combined treatment over one year following the last TACE
- No baseline, in between or after combined treatment imaging
- Lesion appeared after TACE treatment
Key Trial Info
Start Date :
January 4 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2021
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT04813861
Start Date
January 4 2010
End Date
March 1 2021
Last Update
March 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Nancy
Nancy, France, 54000